U.S. Health Resources and Services Administration (HRSA) Acting Administrator Diana Espinosa this morning informed six pharmaceutical manufacturers that their restrictions on 340B program pricing to covered entities that dispense medications through contract pharmacies have resulted in overcharges and are in direct violation of the 340B statute.
HRSA announced its decisions about the companies’ policies on the Office of Pharmacy Affairs home page. It was a major turning point in the nearly year-long fight over whether drug makers are obligated to offer 340B pricing on their products when covered entities use contract pharmacies to dispense them. HRSA said it “has conducted a review of these actions and an analysis of complaints received from covered entities, resulting in today’s letters.”
U.S. Health Resources and Services Administration (HRSA) Acting Administrator Diana Espinosa this morning informed six pharmaceutical manufacturers that their restrictions on 340B program pricing to covered entities that dispense medications through contract pharmacies have resulted in overcharges and are in direct violation of the 340B statute.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
